Facio’s parent publishes Annual Report 2018


Leiden, the Netherlands - April 8, 2019

Facio Therapies announced today that its parent company, FSHD Unlimited, published its Annual Report for the year 2018. Facio is the only privately held company in the FSHD space to publish full annual reports, including audited annual accounts. Facio’s Annual Report 2018 consists of a Board Report, the audited accounts, and an auditor’s report. The… read more

Facio expands portfolio with 100+ novel, chemically diverse DUX4 repressors


Leiden, the Netherlands - March 21, 2019

Facio Therapies announced today that it has significantly expanded its portfolio of DUX4 repressors. After rigorous selection, Facio identified over 100 novel, chemically diverse small molecules that repress production of the human DUX4 protein in cultured FSHD-affected muscle cells. Facio is the only company known to have a pipeline of proprietary, chemically diverse small molecules… read more